Acumen Pharmaceuticals Inc (NASDAQ:ABOS) price on Thursday, July 03, rose 2.65% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.16.
A look at the stock’s price movement, the close in the last trading session was $1.13, moving within a range at $1.13 and $1.17. The beta value (5-Year monthly) was 0.05. Turning to its 52-week performance, $3.60 and $0.86 were the 52-week high and 52-week low respectively. Overall, ABOS moved 11.54% over the past month.
Acumen Pharmaceuticals Inc’s market cap currently stands at around $70.27 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-13.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ABOS is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 3 recommend ABOS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ABOS’s current price about -1.11% and 6.16% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 51.76, while 7-day volatility ratio is 5.57% and 7.28% in the 30-day chart. Further, Acumen Pharmaceuticals Inc (ABOS) has a beta value of 0.11. Analysts have given the company’s stock an average 52-week price target of $7, forecast between a low of $7 and high of $7. Looking at the price targets, the low is -503.45% off current price level while to achieve the yearly target high, price needs to move -503.45%. Nonetheless, investors will most likely welcome a -503.45% jump to $7 which is the analysts’ median price.
If we refocus on Acumen Pharmaceuticals Inc (NASDAQ:ABOS), historical trading data shows that trading volumes averaged 0.83 over the past 10 days and 342.50K over the past 3 months. The company’s latest data on shares outstanding shows there are 60.57 million shares.
The 27.03% of Acumen Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 58.48% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.68 million on 2025-06-13, giving us a short ratio of 10.96. The data shows that as of 2025-06-13 short interest in Acumen Pharmaceuticals Inc (ABOS) stood at 596.0 of shares outstanding, with shares short rising to 1.88 million registered in 2025-05-15. Current price change has pushed the stock -51.36% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ABOS stock continues to rise going into the next quarter.
